We are live on ! Find out more
STLN

Starling Oncology Institute, Inc. Common Stock

108 hedge funds and large institutions have $121M invested in Starling Oncology Institute, Inc. Common Stock in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,185% more call options, than puts

Call options by funds: $3.55M | Put options by funds: $108K

483% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 6

85% more capital invested

Capital invested by funds: $65.5M → $121M (+$55.5M)

38% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 24

37% more funds holding

Funds holding: 79108 (+29)

2.33% more ownership

Funds ownership: 34.75%37.08% (+2.3%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
108
Holders Change
+29
Holders Change %
+36.71%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
35
Increased
33
Reduced
24
Closed
6
Calls
$3.55M
Puts
$108K
Net Calls
+$3.44M
Net Calls Change
+$3.44M

STLN Hedge Fund Activity: Q3 2025 in Review

108 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q3 2025, worth a combined $121M — up 85% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new STLN positions and 6 closed out — a net gain of 29 holders — while 33 added to existing stakes and 24 trimmed.

The largest buyer was CenterBook Partners, adding an estimated $6.81M. The largest seller was TIFF Advisory Services, cutting an estimated $9.52M.

  • 108 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q3 2025, up from 79 in Q2 2025.
  • Funds reported $121M of Starling Oncology Institute, Inc. Common Stock stock for Q3 2025, up 85% quarter-over-quarter.
  • 35 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q3 2025 and 6 closed out, a net change of +29 holders.
  • The largest Starling Oncology Institute, Inc. Common Stock buyer in Q3 2025 was CenterBook Partners, an estimated $6.81M added.
  • The largest Starling Oncology Institute, Inc. Common Stock seller in Q3 2025 was TIFF Advisory Services, an estimated $9.52M sold.

Based on aggregated 13F filings for Q3 2025.